The central focus of the BIO-DrIM project (BIOmarker-Driven personalized IMmunosuppression) is the implementation of biomarker-driven strategies for personalizing immunosuppression.
Due to the progresses in the pharmacologic immunosuppressive treatments of transplanted patients, there are very good results in short-term graft survival, but the long-term graft and patient survival remain almost unchanged and unsatisfactory. Moreover, there are severe adverse effects of long-term immunosuppression such as graft toxicity, diabetes, cardiovascular events, opportunistic and community acquired infections, bone loss, and malignancies continue to challenge the long-term success of transplantation. Long-term immunosuppression results in high direct (drug) and indirect (management of adverse effects) costs.
The opportunities for biomarker-driven personalized immunosuppression are exiting, offering the best treatment to each single patient after transplantation. Validated biomarkers will enable the characterization of patient populations and their stratification. It will allow to optimize the personalized immunosuppressive therapy to improve the quality of life of transplant patients, to decrease the adverse effects and costs of chronic immunosuppression, thus improving the long-term outcome of transplantations.
Project full title: Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation
Project Coordinator: Prof. Dr. Petra Reinke, Department of Nephrology and Internal Intensive Medicine, Charité - University Medicine Berlin & Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Germany
EC Contribution: € 6 million
Start date: 01/11/2012
Duration: 60 months